




Toujeo® is associated with a more stable and prolonged activity profile over a full 24-hour period than insulin glargine 100 units/mL^{1,2}



Toujeo®
insulin glargine 100 units/mL

PK/PD data in T1DM patients using euglycaemic-clamp technique

Activity profile at steady state in T1DM patients 0.4 units/kg/day^{1,2}



For GIR data, a smoothing factor (LOESS factor 0.15) was applied.

Adapted from Becker, *et al.* 2015.

Toujeo® has a flatter, more stable activity profile – extending beyond 24 hours with a flexible dosing window (+/- 3 hours).

- The clinical implications of PK/PD data require further evaluation including CGM studies and larger clinical studies
- PK/PD study in people with T1DM using euglycaemic-clamp technique at steady state. The results of euglycaemic clamp studies do not necessarily predict clinical outcomes in all patients

CGM, continuous glucose monitoring; GIR, glucose infusion rate; LOESS, locally weighted scatter plot smoother; PD, pharmacodynamic; PK, pharmacokinetic; SC, subcutaneous; T1DM, type 1 diabetes mellitus.

1. Becker R, et al. *Diabetes Care*. 2015;38:637–643; 2. Toujeo® Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/6938/smpc>. [Accessed: June 2023].